BioTech Pharma
HomeCatalogTirzepatide
Tirzepatide research vial

2D Molecular Structure

Tirzepatide 2D molecular structure for compound 156588324
CID
156588324
Standard InChIKey
AAPYRSPHYSKGIS-MCNPHUAVSA-N
FDA UNII
OYN3CCI6QE
Residue Count
39 AA
Structural Modifications
  • Aib substitutions at positions 2 and 13
  • Lys20 side chain conjugated via γGlu-γGlu linker to a C20 fatty-diacid (eicosanedioic acid)
  • C-terminal amide
metabolic Research

Tirzepatide

Also known as: LY3298175

Dual GIP/GLP-1 receptor agonist peptide studied in incretin-pathway and metabolic research, supplied as a lyophilized powder.
CAS Number
2023788-19-2
Molecular Formula
C225H348N48O68
Molecular Weight
4813.5 g/mol
Purity
Batch-specific
Form
Lyophilized powder
Enquiry Sizes
5 mg • 10 mg • 15 mg • Bulk API (gram+)
Peptide Sequence39 residues
Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Compliance Notice: All products supplied by BioTech Pharma are intended strictly for laboratory research and development use only. They are not intended for human or veterinary use, diagnosis, treatment, or consumption of any kind. By submitting an enquiry, the requester confirms they are a qualified researcher or institution and accepts full responsibility for compliant handling and use.

Configure Your Request

Documentation requests are reviewed against the records available for the applicable lot. Availability, methods, and values must be confirmed for the specific enquiry and are not promised in advance.

Form supplied: Lyophilized powder. Your selections are carried into the quote request automatically.

Overview

Tirzepatide is a 39-amino-acid synthetic peptide engineered from the native GIP sequence and modified with a C20 fatty-diacid moiety. It acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, making it one of the most studied molecules in contemporary incretin research.

In preclinical and mechanistic studies, dual incretin receptor engagement has been studied in relation to insulin secretion dynamics, glucagon regulation, gastric emptying, appetite signaling, and adipose tissue biology. These are preclinical and in-vitro observations that do not establish clinical efficacy; its balanced receptor pharmacology makes it a reference compound for comparative agonist-signaling work.

BioTech Pharma supplies tirzepatide as a lyophilized powder for laboratory research use only. Lot-specific analytical documentation may be available and should be confirmed for the applicable material. Availability and commercial terms, including bulk quantities for institutional programs, are confirmed per enquiry.

Research Applications

  • Dual incretin (GIP/GLP-1) receptor pharmacology
  • Glucose homeostasis and insulin-secretion models
  • Appetite regulation and energy-balance studies
  • Adipose tissue and lipid-metabolism research
  • Comparative agonist signaling and receptor selectivity

Frequently Asked Questions

Scientific References

Analytical Data

Lot-specific documentation may be available for the applicable material and must be confirmed per enquiry. Where available, it may include:

  • HPLC purity result
  • LC-MS identity confirmation
  • Appearance
  • Net content

Request the records you need with your quote and we will confirm availability for your batch.

Procurement Details

Availability, lead time, salt / content basis, and cold-chain requirements depend on the specific lot and quantity, so we confirm them per enquiry rather than publishing fixed figures. Request confirmation for your requirements with your quote and our team will respond with details for the applicable batch.

Storage & Handling

Lyophilized: store at −20 °C, protected from light. Reconstituted: keep at 2–8 °C and determine working-solution stability empirically per lot, as reconstituted stability varies with diluent, concentration, and handling.

Related Compounds